Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation

M. Zambetti, A. Moliterni, C. Materazzo, M. Stefanelli, S. Cipriani, P. Valagussa, G. Bonadonna, L. Gianni

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Purpose: To investigate long-term cardiac sequelae associated with anthracycline use in adjuvant chemotherapy of patients with early breast cancer. Patients and Methods: All 1,000 patients from three prospective trials of adjuvant chemotherapy containing doxorubicin (n = 637, median total dose of 294 mg/m2) or not containing the anthracycline (cyclophosphamide, methotrexate, and fluorouracil [CMF] regimen alone, n = 363) were analyzed for the relative incidence of congestive heart failure (CHF) and myocardial infarction (MI) during 14 years of follow-up. The 462 women continuously free of disease as of February 1996 were recalled, and 355 consented to undergo evaluation including 12-lead ECG and cardiac ultrasound with determination of left ventricular ejection fraction (LVEF) to assess the relative incidence of abnormalities in long-term survivors. Results: Among the 1,000 patients, there were six cases of CHF and three cases of MI. Cumulative cardiac mortality accounted far 0.4% (doxorubicin-treated = 0.6%; CMF-treated = 0). Eighteen (5%) of the 355 patients undergoing cardiac evaluation after median 11 years of follow-up presented systolic dysfunction as defined by pathologic (<50%, n = 8) or borderline (50% to 55%, n = 10) LVEF. Systolic dysfunction was higher in doxorubicin-treated (15 of 192; 8%) than in CMF-treated patients (three of 150; 2%). Breast irradiation had a significant impact on the occurrence of early CHF (four of 116; 3%), but not on systolic dysfunctions. Conclusion: At longer than 10 years of follow-up, the use of doxorubicin at a total dose commonly applied in regimens of adjuvant chemotherapy does not lead to cardiac clinical sequelae that counter-balance the benefit of treatment in patients with operable breast cancer who may be cured of their disease.

Original languageEnglish
Pages (from-to)37-43
Number of pages7
JournalJournal of Clinical Oncology
Volume19
Issue number1
Publication statusPublished - Jan 1 2001

Fingerprint

Adjuvant Chemotherapy
Doxorubicin
Breast
Breast Neoplasms
Methotrexate
Fluorouracil
Cyclophosphamide
Heart Failure
Anthracyclines
Stroke Volume
Myocardial Infarction
Incidence
Survivors
Electrocardiography
Mortality

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. / Zambetti, M.; Moliterni, A.; Materazzo, C.; Stefanelli, M.; Cipriani, S.; Valagussa, P.; Bonadonna, G.; Gianni, L.

In: Journal of Clinical Oncology, Vol. 19, No. 1, 01.01.2001, p. 37-43.

Research output: Contribution to journalArticle

Zambetti, M, Moliterni, A, Materazzo, C, Stefanelli, M, Cipriani, S, Valagussa, P, Bonadonna, G & Gianni, L 2001, 'Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation', Journal of Clinical Oncology, vol. 19, no. 1, pp. 37-43.
Zambetti, M. ; Moliterni, A. ; Materazzo, C. ; Stefanelli, M. ; Cipriani, S. ; Valagussa, P. ; Bonadonna, G. ; Gianni, L. / Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. In: Journal of Clinical Oncology. 2001 ; Vol. 19, No. 1. pp. 37-43.
@article{7b7ce55ad7b4451483a6a7724438cb2e,
title = "Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation",
abstract = "Purpose: To investigate long-term cardiac sequelae associated with anthracycline use in adjuvant chemotherapy of patients with early breast cancer. Patients and Methods: All 1,000 patients from three prospective trials of adjuvant chemotherapy containing doxorubicin (n = 637, median total dose of 294 mg/m2) or not containing the anthracycline (cyclophosphamide, methotrexate, and fluorouracil [CMF] regimen alone, n = 363) were analyzed for the relative incidence of congestive heart failure (CHF) and myocardial infarction (MI) during 14 years of follow-up. The 462 women continuously free of disease as of February 1996 were recalled, and 355 consented to undergo evaluation including 12-lead ECG and cardiac ultrasound with determination of left ventricular ejection fraction (LVEF) to assess the relative incidence of abnormalities in long-term survivors. Results: Among the 1,000 patients, there were six cases of CHF and three cases of MI. Cumulative cardiac mortality accounted far 0.4{\%} (doxorubicin-treated = 0.6{\%}; CMF-treated = 0). Eighteen (5{\%}) of the 355 patients undergoing cardiac evaluation after median 11 years of follow-up presented systolic dysfunction as defined by pathologic (<50{\%}, n = 8) or borderline (50{\%} to 55{\%}, n = 10) LVEF. Systolic dysfunction was higher in doxorubicin-treated (15 of 192; 8{\%}) than in CMF-treated patients (three of 150; 2{\%}). Breast irradiation had a significant impact on the occurrence of early CHF (four of 116; 3{\%}), but not on systolic dysfunctions. Conclusion: At longer than 10 years of follow-up, the use of doxorubicin at a total dose commonly applied in regimens of adjuvant chemotherapy does not lead to cardiac clinical sequelae that counter-balance the benefit of treatment in patients with operable breast cancer who may be cured of their disease.",
author = "M. Zambetti and A. Moliterni and C. Materazzo and M. Stefanelli and S. Cipriani and P. Valagussa and G. Bonadonna and L. Gianni",
year = "2001",
month = "1",
day = "1",
language = "English",
volume = "19",
pages = "37--43",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation

AU - Zambetti, M.

AU - Moliterni, A.

AU - Materazzo, C.

AU - Stefanelli, M.

AU - Cipriani, S.

AU - Valagussa, P.

AU - Bonadonna, G.

AU - Gianni, L.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Purpose: To investigate long-term cardiac sequelae associated with anthracycline use in adjuvant chemotherapy of patients with early breast cancer. Patients and Methods: All 1,000 patients from three prospective trials of adjuvant chemotherapy containing doxorubicin (n = 637, median total dose of 294 mg/m2) or not containing the anthracycline (cyclophosphamide, methotrexate, and fluorouracil [CMF] regimen alone, n = 363) were analyzed for the relative incidence of congestive heart failure (CHF) and myocardial infarction (MI) during 14 years of follow-up. The 462 women continuously free of disease as of February 1996 were recalled, and 355 consented to undergo evaluation including 12-lead ECG and cardiac ultrasound with determination of left ventricular ejection fraction (LVEF) to assess the relative incidence of abnormalities in long-term survivors. Results: Among the 1,000 patients, there were six cases of CHF and three cases of MI. Cumulative cardiac mortality accounted far 0.4% (doxorubicin-treated = 0.6%; CMF-treated = 0). Eighteen (5%) of the 355 patients undergoing cardiac evaluation after median 11 years of follow-up presented systolic dysfunction as defined by pathologic (<50%, n = 8) or borderline (50% to 55%, n = 10) LVEF. Systolic dysfunction was higher in doxorubicin-treated (15 of 192; 8%) than in CMF-treated patients (three of 150; 2%). Breast irradiation had a significant impact on the occurrence of early CHF (four of 116; 3%), but not on systolic dysfunctions. Conclusion: At longer than 10 years of follow-up, the use of doxorubicin at a total dose commonly applied in regimens of adjuvant chemotherapy does not lead to cardiac clinical sequelae that counter-balance the benefit of treatment in patients with operable breast cancer who may be cured of their disease.

AB - Purpose: To investigate long-term cardiac sequelae associated with anthracycline use in adjuvant chemotherapy of patients with early breast cancer. Patients and Methods: All 1,000 patients from three prospective trials of adjuvant chemotherapy containing doxorubicin (n = 637, median total dose of 294 mg/m2) or not containing the anthracycline (cyclophosphamide, methotrexate, and fluorouracil [CMF] regimen alone, n = 363) were analyzed for the relative incidence of congestive heart failure (CHF) and myocardial infarction (MI) during 14 years of follow-up. The 462 women continuously free of disease as of February 1996 were recalled, and 355 consented to undergo evaluation including 12-lead ECG and cardiac ultrasound with determination of left ventricular ejection fraction (LVEF) to assess the relative incidence of abnormalities in long-term survivors. Results: Among the 1,000 patients, there were six cases of CHF and three cases of MI. Cumulative cardiac mortality accounted far 0.4% (doxorubicin-treated = 0.6%; CMF-treated = 0). Eighteen (5%) of the 355 patients undergoing cardiac evaluation after median 11 years of follow-up presented systolic dysfunction as defined by pathologic (<50%, n = 8) or borderline (50% to 55%, n = 10) LVEF. Systolic dysfunction was higher in doxorubicin-treated (15 of 192; 8%) than in CMF-treated patients (three of 150; 2%). Breast irradiation had a significant impact on the occurrence of early CHF (four of 116; 3%), but not on systolic dysfunctions. Conclusion: At longer than 10 years of follow-up, the use of doxorubicin at a total dose commonly applied in regimens of adjuvant chemotherapy does not lead to cardiac clinical sequelae that counter-balance the benefit of treatment in patients with operable breast cancer who may be cured of their disease.

UR - http://www.scopus.com/inward/record.url?scp=0035152095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035152095&partnerID=8YFLogxK

M3 - Article

C2 - 11134193

AN - SCOPUS:0035152095

VL - 19

SP - 37

EP - 43

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -